Introduction {#S1}
============

Chronic graft-versus-host disease (cGVHD) remains a major cause of long-term morbidity, mortality, and poor quality of life following allogeneic hematopoietic stem cell transplantation (allo-HSCT) ([@B1], [@B2]). One hurdle in the development of preventive and therapeutic strategies against cGVHD is the complex origins and maintenance mechanisms of the pathogenic immune cells that are involved in this protracted disease. Despite clinical and experimental evidence that mature T cells in the graft (T~G~) are responsible for tissue injury during acute GVHD (aGVHD), the contribution of T~G~ to the pathogenesis of cGVHD remains poorly understood.

After allo-HSCT, host-reactive T~G~ are primed by host-type professional antigen-presenting cells (APCs) *via* the direct allo-recognition pathway in the secondary lymphoid organs, where they expand and differentiate into host-reactive effector T~G~ ([@B3], [@B4]). Effector T~G~ then redistribute to the target organs of aGVHD, such as the skin, liver, intestine, and hematopoietic and lymphoid tissues, where they impair host tissue function. Of note, an indirect allo-recognition pathway in which donor bone marrow (BM)-derived APCs repopulate peripheral tissues, uptake host-type antigens, and present them to donor T cells maximizes GVHD in a CD8-dependent GVHD model ([@B5]). Interestingly, *in vivo* early T cell depletion by antithymocyte globulin ([@B6], [@B7]) or post-transplant cyclophosphamide ([@B8]--[@B10]) reduces cGVHD rather than aGVHD. These clinical observations suggest a role for T~G~ in the development of cGVHD, but this is difficult to examine in a human setting, and experimental evidence demonstrating the contribution of long-lasting T~G~ to the development of cGVHD is lacking.

Since non-hematopoietic cells in the target organs remain as host-type even after allo-HSCT, T~G~ are continuously exposed to cognate antigens, which theoretically induce deletion, anergy, or replicative senescence in T~G~ ([@B11], [@B12]). In contrast to T~G~, which lack *de novo* replenishment, donor HSC-derived T cells (T~HSC~) that have undergone thymic selection are continuously replenished from the thymus, and thus T~HSC~ rather than T~G~ have been implicated in the pathogenesis of cGVHD ([@B13]--[@B15]). On the other hand, Hossain et al. ([@B16]) have shown that functional T~G~ persisted up to 100 days after allo-HSCT in a cGVHD model and that the persisting T~G~ confer protection against murine cytomegalovirus infection. This finding suggests that persisting T~G~ could be a functional population with a role in the pathogenesis of cGVHD.

In the present study, using a minor-mismatched allo-HSCT model in which the GVHD recipients display histopathology characteristic of cGVHD, we characterized the kinetics, function, and antigen reactivity of T~G~ and T~HSC~. Selective depletion of T~G~ or T~HSC~ in the chronic phase of disease revealed that persisting T~G~ suppress the accumulation of T~HSC~ in cGVHD-affected organs, whereas T~HSC~ suppress the lethal activation of T~G~ in affected organs.

Materials and Methods {#S2}
=====================

Mice {#S2-1}
----

Female C57BL/6J (B6; H-2^b^, CD45.2, Thy1.2) mice were purchased from CLEA Japan. C57BL/6J.SJL (B6.SJL; Ptprca Pepcb, CD45.1, Thy1.2), C3H.SW-H2b (B6; H-2^b^, CD45.2, Thy1.2), and C57BL/6J-Igh^a^-Thy1^a^-Gpi^a^ (B6.Thy1a; CD45.2, Thy1.1) mice were purchased from the Jackson Laboratory. B6 background congenic strains were crossed in-house to obtain CD45.1^+^ CD45.2^+^ Thy1.2^+^ and CD45.1^+^ CD45.2^+^ Thy1.1^+^ congenic strains. All animal experiments were conducted in accordance with institutional guidelines with the approval of the Animal Care and Use Committee of the University of Tokyo.

Transplantation and Assessment of GVHD {#S2-2}
--------------------------------------

Cell preparation and allo-HSCT were performed as described previously ([@B17], [@B18]) with some modifications. In brief, T-cell-depleted BM (TCD BM) was prepared by depleting Thy1^+^ mature T cells from BM using an autoMACS system (Miltenyi Biotec). Splenic T cells were negatively enriched from splenocytes by autoMACS, using antibodies against CD11b, CD11c, B220, Ter-119, NK1.1, and c-kit. Recipients were lethally irradiated (9 Gy, split into two doses given 3 h apart) on day −1, then injected intravenously with 5 × 10^6^ TCD BM cells with or without 3--4 × 10^6^ splenic T cells on day 0. The development of systemic GVHD was quantified by measuring weight loss and using a clinical GVHD scoring system, as described previously ([@B19]).

Histological Analyses {#S2-3}
---------------------

For the assessment of pathological changes in tissues, 4--6-µm formalin-fixed paraffin sections were stained with H&E and assessed by a pathologist (Teppei Morikawa; blinded to experimental group) using a scoring system described previously ([@B20]--[@B22]). For immunohistological analyses, the left lobes of the lung were inflated by infusion of 500 µl OCT compound intratracheally before lung tissue was harvested. Acetone-fixed 6- to 8-µm cryosections were incubated sequentially with primary antibodies and the appropriate fluorochrome-labeled secondary antibodies after blocking. Sections were mounted with Prolong Gold Antifade Reagent (Life Technologies) and visualized using an SP-5 confocal microscope (Leica Microsystems).

Cell Preparation {#S2-4}
----------------

Single cell suspensions were prepared from the liver, lung, spleen, BM and thymus after systemic transcardial perfusion with PBS. Liver cells were prepared by pressing liver tissue through a 200-µm stainless steel mesh ([@B23]). The right lobe of lung tissue was cut into small fragments and digested for 1 h at 37°C with 0.2% collagenase D (Roche, Penzberg, Germany) and 2,000 U/ml DNase I (Calbiochem, La Jolla, CA, USA). BM cells were flushed from femurs using a needle and syringe. Spleen and thymus tissue were pressed through a 70-µm cell strainer. Non-hematopoietic cells and cell debris were removed by 40% Percoll (GE healthcare) phase separation, and erythrocytes were removed using ACK lysing buffer.

Flow Cytometry {#S2-5}
--------------

Labeled and purified antibodies were purchased from BD Biosciences, BioLegend, or eBioscience (Table [1](#T1){ref-type="table"}). Single cell suspensions were incubated sequentially with anti-CD16/32 (to block Fc receptors) then primary antibodies. Data were collected on a Gallios flow cytometer (Beckman Coulter) and analyzed using FlowJo software (Tree Star). For intracellular cytokine analysis, 5--10 × 10^5^ leukocytes were restimulated with ionomycin (1 µg/ml) and PMA (25 ng/ml) in the presence of Brefeldin A (10 µg/ml) for 4.5--5 h at 37°C. Following staining for surface antigens, cells were stained for intracellular cytokines using a Cytofix/Cytoperm kit (BD Bioscience), according to the manufacturer's instructions. For short-term pulse BrdU labeling, mice were injected intraperitoneally with 1 mg/mouse BrdU (Sigma-Aldrich) in 100 µl PBS 1 h before sacrifice. BrdU incorporation was examined using a BrdU flow kit (BD Biosciences), according to the manufacturer's instructions. For the intracellular staining of Foxp3 and Ki-67, 1 × 10^6^ leukocytes were stained for surface antigens and then were fixed and permeabilized with Foxp3 Fix/Perm Buffer (eBioscience) according to the manufacturer's instructions.

###### 

List of antibodies used for flow cytometry.

  Antigen           Clone                    Manufacturer
  ----------------- ------------------------ ----------------
  CD3ε              145-2C11                 BD Biosciences
  CD4               RM4-4                    BioLegend
  CD8α              53-6.7                   BioLegend
  CD11b             M1/70                    BD Biosciences
  CD16/32           2.4G2                    BioXcell
  CD25              PC61                     BD Biosciences
  CD44              IM7                      BD Biosciences
  CD45.1            A20                      BioLegend
  CD45.2            104                      BD Biosciences
  B220              RA3-6B2                  BioLegend
  CD48              HM48-1                   BioLegend
  CD62L             MEL-14                   BD Biosciences
  CD69              H1.2F3                   BD Biosciences
  CD90.1            OX-7                     BioLegend
  CD90.2            53-2.1                   BD Biosciences
  CD117 (c-Kit)     2B8                      BD Biosciences
  CD127 (IL-7Rα)    A7R34                    BioLegend
  CD150             TC15-12F12.2             BioLegend
  Ly-6A/E (Sca-1)   D7                       BioLegend
  LAG-3             C9B7W                    eBioscience
  CD279 (PD-1)      J43                      eBioscience
  CD279 (PD-1)      RMP1-30                  BioLegend
  Ly-6C/G (Gr-1)    RB6-8C5                  BioLegend
  NK1.1             PK136                    BD Biosciences
  Ter-119           TER-119                  BioLegend
  Foxp3             FJK-16s                  eBioscience
  KLRG-1            2F1/KLRG1                BioLegend
  BrdU              B44                      BD Biosciences
  Ki-67             SolA1s                   eBioscience
  TCR-β             H57-597                  BD Biosciences
  IFN-γ             XMG1.2                   BioLegend
  TNF-α             MP6-XT22                 BD Biosciences
  Granzyme B        GB11                     BioLegend
  Streptavidin                               BioLegend
  Collagen I        Rabbit anti-serum        LSL
  Lyve-1            Goat IgG, polyclonal     R&D
  PanEndothelial    MECA-32                  BioLegend
  Rabbit IgG        Donkey IgG, polyclonal   Thermo Fisher
  Goat IgG          Donkey IgG, polyclonal   Thermo Fisher
  Rat IgG           Donkey IgG, polyclonal   Thermo Fisher

*Ex Vivo* and *In Vivo* Proliferation Assays {#S2-6}
--------------------------------------------

Chronic graft-versus-host disease was induced by transferring CD45.1^+^ Thy1.1^+^ TCD BM and CD45.1^+^ Thy1.2^+^ splenic T cells. Single cell suspensions of the liver and lung were prepared on day 49, and total T cells were enriched by negative selection with antibodies against CD11b, CD31, CD140a, CD326, B220, NK1.1, and Ter-119. T~G~ and T~HSC~ were enriched from the T cell fraction using positive selection with antibodies against Thy1.2 and Thy1.1, respectively, and used as secondary donors in *in vivo* proliferation assays, or as responders in the *ex vivo* proliferation assay. Non-hematopoietic cells were prepared from the lung of untreated C3H.SW-H2b mice or day 49 BMT recipients by negative selection with antibodies against CD45 and Ter-119. CD3^−^ NK1.1^−^ hematopoietic cells were prepared from the spleen of untreated C3H.SW-H2b mice or day 49 BMT recipients by negative selection with antibodies against CD3 and NK1.1. In an *ex vivo* proliferation assay, T~G~ and T~HSC~ were labeled with 5 µM CFSE and were cocultured with the non-hematopoietic cells or CD3^−^ NK1.1^−^ hematopoietic cells at a ratio of 1:10 for 3 days. In an *in vivo* proliferation assays, CFSE-labeled T~G~ and T~HSC~ were equally mixed and transferred intravenously into day 49 BMT recipients reconstituted with CD45.2 TCD BM.

*In Vivo* T Cell Depletion {#S2-7}
--------------------------

To deplete T~G~ or T~HSC~ selectively, recipient mice expressing various combinations of the congenic markers Thy1.1 and Thy1.2 were injected intraperitoneally with purified rat IgG2b anti-mouse Thy1.2 mAb (clone 30H12, BioXcell) on days 21 (200 µg) and 24 (100 µg) after allo-HSCT, followed by weekly administration (200 µg) from days 31--63.

Statistical Analyses {#S2-8}
--------------------

All values are expressed as mean ± SEM. All data are representative of results obtained in at least two independent internally controlled experiments, where intergroup effects observed within each experiment were consistent across all experiments. Survival curves for GVHD were plotted using Kaplan--Meier estimates and compared by log-rank analysis (Prism version 5.0; GraphPad Prism Software). Comparisons between two groups were performed by unpaired two-tail Student's *t*-tests. Multiple comparisons were performed by one-way ANOVA with Dunnett's post-test. *P*-Values less than 0.05 were considered to be statistically significant.

Results {#S3}
=======

Establishment of a Clinically Relevant Model of cGVHD {#S3-1}
-----------------------------------------------------

We first established a B6→C3H.SW minor-mismatched cGVHD model to facilitate identification and manipulation of T~G~ and T~HSC~ populations using CD45 and Thy1 congenic markers. Lethally irradiated C3H.SW recipients were transplanted with TCD BM alone ("BMT group") or TCD BM with splenic T cells ("cGVHD group") from B6 donors. In the cGVHD group, body weight loss and GVHD score became progressively worse from day 14 onward (Figures [1](#F1){ref-type="fig"}A,B), and cGVHD mice had a significantly lower survival rate (Figure [1](#F1){ref-type="fig"}C). At day 63, the histology of the salivary glands (SG), skin, liver, and lung revealed inflammatory cell infiltration and fibrotic changes, which are the most relevant histological features in the diagnosis of human cGVHD (Figures [1](#F1){ref-type="fig"}D,E) ([@B24], [@B25]). The pathological scores for these organs were higher in cGVHD mice compared to BMT control mice, reaching statistical significance in the SG and liver (Figure [1](#F1){ref-type="fig"}F). These results demonstrate that cGVHD mice in the B6→C3H.SW minor-mismatched allo-HSCT model develop pathology that recapitulates human cGVHD.

![Establishment of a clinically relevant model of chronic graft-versus-host disease (cGVHD). Lethally irradiated C3H.SW mice were transplanted with T-cell-depleted bone marrow (TCD BM) alone or TCD BM plus 3--4 × 10^6^ T cells from the spleens of B6 mice. **(A)** Body weight, **(B)** GVHD score, and **(C)** survival were monitored for 63 days after transplantation. Data are combined from three independent experiments (*n* = 21 for BMT control group; *n* = 29 **(A,B)**; or *n* = 44 **(C)** for cGVHD group). **(D)** Salivary glands (SG), skin, liver, and lung were collected 63 days after transplantation for examination of pathology by HE staining. Scale bars, 50 µm. **(E)** Immunofluorescent staining of liver and lung sections. Green, pan-endothelial; red, collagen; and blue, Lyve1. **(F)** Histological scores from SG, skin, liver, and lung. Data are combined from two independent experiments (*n* = 5 for BMT control group; *n* = 8 for cGVHD groups). \**P* ≤ 0.05; \*\**P* ≤ 0.01; and \*\*\**P* ≤ 0.001 (cGVHD vs. BMT).](fimmu-08-01842-g001){#F1}

T~G~ Predominate over T~HSC~ in cGVHD-Affected Organs {#S3-2}
-----------------------------------------------------

We next examined the kinetics of T~G~ and T~HSC~ in our cGVHD model using CD45 congenic markers (Figure [2](#F2){ref-type="fig"}A). The number of CD4^+^ CD8^+^ thymocytes of CD45.1^+^ CD45.2^+^ TCD BM origin (T~HSC~) in cGVHD mice increased markedly between days 21 and 35 (Figure [2](#F2){ref-type="fig"}B). In peripheral tissues such as the liver, lung, and spleen, detectable numbers of T~HSC~ appeared from day 21 after HSCT, but within the CD8^+^ T cell populations of these tissues, T~G~ outnumbered T~HSC~ approximately 10-fold for the duration of our experiments (Figure [2](#F2){ref-type="fig"}C). A similar trend was observed in CD4^+^ T cell populations. Interestingly, T~G~ were more abundant than T~HSC~ within CD4^+^ Foxp3^+^ regulatory T cells in the liver by day 35; however, there was a trend toward T~HSC~ dominance by day 63 (Figure [2](#F2){ref-type="fig"}D). Immunofluorescent staining of the liver showed that both Foxp3^+^ CD4^+^ T~G~ and Foxp3^+^ CD4^+^ T~HSC~ were uniformly distributed throughout the T cell pool at day 63 (Figure [2](#F2){ref-type="fig"}E). These results suggest that T~G~ rather than T~HSC~ persist as the dominant CD8^+^ T cell population, while T~HSC~ gradually become the dominant CD4^+^ T cell population, particularly within the Foxp3^+^ CD4^+^ regulatory T cell populations in cGVHD-affected organs.

![T~G~ predominate over T~HSC~ in chronic graft-versus-host disease (cGVHD)-affected organs. CD45.1^+^ CD45.2^+^ T-cell-depleted bone marrow (TCD BM) and CD45.1^+^ CD45.2^−^ spleen T cells from B6 donor mice were transferred into CD45.1^−^ CD45.2^+^ C3H.SW-recipient mice. **(A)** Representative flow cytometry plot of TCRβ^+^ T cells showing how congenic markers were used to detect T cells from distinct origins. CD45.1^+^ CD45.2^+^ cells represent T~HSC~ cells derived from BM HSC. CD45.1^+^ CD45.2^−^ T cells represent T~G~ derived from mature T cells in the graft. **(B)** The number of CD4^+^ CD8^+^ thymocytes of CD45.1^+^ CD45.2^+^ TCD BM origin (T~HSC~) was used as an indicator of immune reconstitution in the thymus. Representative data are shown from one of two independent experiments (*n* = 4). **(C)** Numbers of T~G~ and T~HSC~ collected from the liver (per gram), lung, and spleen following allogeneic hematopoietic stem cell transplantation (allo-HSCT). **(D)** The proportion of Foxp3^+^ cells within the liver CD4^+^ cell population following allo-HSCT. Data represent mean ± SEM (*n* = 5--7 per time point) and are combined from two independent experiments. **(E)** CD45.1^+^ TCD BM and CD45.2^+^ spleen T cells from B6 donor mice were transferred into C3H.SW-recipient mice, and the localization of CD4^+^ Foxp3^+^ T cells of CD45.1^+^ (T~HSC~) or CD45.1^−^ (T~G~) origin in the liver was analyzed on day 63. Green, CD4; red, CD45.1; and blue, Foxp3. Scale bar, 50 µm. \**P* ≤ 0.05; \*\**P* ≤ 0.01; \*\*\**P* ≤ 0.001; and \*\*\*\**P* ≤ 0.0001 \[cGVHD vs. BMT **(B)** or T~G~ vs. T~HSC~ **(C)**\].](fimmu-08-01842-g002){#F2}

T~G~ Remain Functional during cGVHD {#S3-3}
-----------------------------------

We next compared the phenotype and function of T~G~ and T~HSC~ in the liver at day 63. Compared to their T~HSC~ counterparts, CD8^+^ T~G~ expressed high levels of the exhaustion markers PD-1 and LAG-3, the senescence/terminal differentiation marker KLRG-1 ([@B11], [@B26]), and low levels of IL-7Rα, which is inversely correlated with alloreactivity ([@B27]) (Figure [3](#F3){ref-type="fig"}A). Expression levels of the early activation marker CD69 were comparable between T~G~ and T~HSC~ (Figure [3](#F3){ref-type="fig"}A). However, we did not observe significant differences in surface marker expression between CD4^+^ T~G~ and CD4^+^ T~HSC~ (Figure [3](#F3){ref-type="fig"}B). Upon *ex vivo* stimulation of liver-infiltrating T cells with PMA and ionomycin, a substantial proportion of CD8^+^ T~G~ produced IFNγ and TNFα at levels that were equal to those produced by their T~HSC~ counterparts (Figure [3](#F3){ref-type="fig"}C). Because T~G~ far outnumbered T~HSC~ in cGVHD-affected organs, the majority of cells with potential to produce inflammatory cytokines in cGVHD-affected organs were of T~G~ origin (Figure [3](#F3){ref-type="fig"}D). A similar trend was observed for CD4^+^ T~G~ and T~HSC~ (Figures [3](#F3){ref-type="fig"}C,D). These results suggest that a substantial proportion of CD4^+^ and CD8^+^ T~G~ persist as a functional population in the target organs of cGVHD.

![T~G~ remain functional during chronic graft-versus-host disease (cGVHD). T cells were collected from the liver 63 days after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Immunophenotype of CD8^+^ **(A)** or CD4^+^ **(B)** T~G~ and T~HSC~ from cGVHD recipients. Representative data are shown from one of two independent experiments (*n* = 6). **(C,D)** Liver T cells were restimulated with PMA and ionomycin *ex vivo* and were analyzed for the intracellular IFNγ and TNFα 63 days after allo-HSCT. **(C)** The percentage of IFNγ^+^ or TNFα^+^ cells within the T~G~ or T~HSC~ populations and **(D)** the absolute numbers of these cells. **(E)** Time-course analyses of PD-1 and KLRG-1 expression on liver-infiltrating T~G~ and T~HSC~. **(F,G)** Populations R1, R2, and R3 from **(E)** were analyzed for the expression of IFNγ, Granzyme B, LAG-3, and Ki-67. Representative plots are shown from one of two independent experiments (*n* = 6). Data represent mean ± SEM (*n* = 6) from one of two independent experiments. \**P* ≤ 0.05; \*\*\**P* ≤ 0.001; and \*\*\*\**P* ≤ 0.0001.](fimmu-08-01842-g003){#F3}

Interestingly, the proportion of PD-1^−^ KLRG-1^+^ cells within the CD8^+^ T~G~ population increased between day 21 and day 63 (Figure [3](#F3){ref-type="fig"}E). To examine whether these PD-1^−^ KLRG-1^+^ cells are functionally distinct from the PD-1^+^ KLRG-1^−^ cells that make up the majority of CD8^+^ T~G~ in early phase, we analyzed the expression of functional molecules and the proliferation marker Ki-67 by these two populations at day 60. The PD-1^+^ KLRG-1^−^ population displayed higher IFNγ production and LAG3 expression than the PD-1^−^ KLRG-1^+^ population, whereas the PD-1^−^ KLRG-1^+^ population displayed higher granzyme B and Ki-67 expression than the PD-1^+^ KLRG-1^−^ population (Figures [3](#F3){ref-type="fig"}F,G). We also compared the functional profiles of the PD-1^+^ KLRG-1^−^ populations from CD8^+^ T~G~ and T~HSC~. Although expression levels of LAG3 and granzyme B were equivalent between T~G~ and T~HSC~, PD-1^+^ KLRG-1^−^ T~HSC~ had lower IFNγ production and significantly higher expression of Ki-67 than their T~G~ counterparts (Figure [3](#F3){ref-type="fig"}G). These results suggest that among CD8^+^ T~G~ the PD-1^+^ KLRG-1^−^ and PD-1^−^ KLRG-1^+^ populations are functionally distinct and that CD8^+^ T~HSC~ have a higher proliferating potential than CD8^+^ T~G~ even when PD-1 expression is equivalent.

Active Proliferation Contributes to the Maintenance of T~G~ during the Chronic Phase {#S3-4}
------------------------------------------------------------------------------------

We next investigated the proliferative responses of T~G~ and T~HSC~ by 1 h *in vivo* BrdU labeling on day 63 after allo-HSCT. The proportion of proliferating (BrdU^+^) cells among liver-infiltrating CD4^+^ T cells was significantly lower within the T~G~ population than in the T~HSC~ population, whereas there was no significant difference in the proportion of BrdU^+^ CD8^+^ T cells (Figure [4](#F4){ref-type="fig"}A). However, in terms of cell number, CD4^+^ BrdU^+^ T~G~ were present in equivalent numbers to CD4^+^ BrdU^+^ T~HSC~, while BrdU^+^ CD8^+^ T~G~ far outnumbered BrdU^+^ CD8^+^ T~HSC~ (Figure [4](#F4){ref-type="fig"}B). To further investigate the proliferative potential of T~G~ and T~HSC~, we prepared T~G~ and T~HSC~ populations from the liver and lung of cGVHD mice and adoptively transferred them into phase-matched BMT recipients on day 49 after allo-HSCT (Figure [4](#F4){ref-type="fig"}C). A CFSE-dilution assay demonstrated that a significant proportion of CD4^+^ and CD8^+^ T~G~, and an even greater proportion of T~HSC~ proliferated 3 days after transfer into secondary BMT recipients (Figures [4](#F4){ref-type="fig"}D,E). These results demonstrate that T~G~ maintain proliferative potential during the chronic phase.

![Proliferative potential and allo-recognition pathway of T~G~ and T~HSC~. **(A,B)** Recipients were injected with BrdU 1 h before sacrifice to enable measurement of cell proliferation in liver T cells. **(A)** Percentage of BrdU^+^ CD4^+^ or CD8^+^ T cells within the T~G~ or T~HSC~ populations on day 63. **(B)** Time-course analysis of the BrdU^+^ T~G~ and T~HSC~ populations in the liver. **(C)** Schematic of *in vivo* proliferation assay. CD45.1^+^ Thy1.1^−^ T~G~ or CD45.1^+^ Thy1.1^+^ T~HSC~ were prepared from the liver and lung of chronic graft-versus-host disease (cGVHD) recipients on day 49. These cells were equally mixed, CFSE-labeled, and transferred to phase-matched BMT recipients that had been reconstituted with CD45.2^+^ T-cell-depleted bone marrow (TCD BM). **(D)** Representative flow cytometry plots showing CFSE dilution in CD45.1^+^ donor cells, which consist of Thy1.1^−^ Thy1.2^+^ T~G~ and Thy1.1^+^ Thy1.2^−^ T~HSC~, in the spleen 3 days after secondary transfer. **(E)** Percentages of T~G~ or T~HSC~ that underwent one or more cell division. **(F)** Schematic of *in vitro* proliferation assay. T~G~ and T~HSC~ were cocultured with lung non-hematopoietic cells or spleen CD3^−^ NK1.1^−^ hematopoietic cells, which were prepared from either untreated C3H mice or BMT recipient C3H mice reconstituted with TCD BM from B6 mice, to determine allo-recognition pathway. **(G)** Percentage of T~G~ or T~HSC~ that underwent one or more cell division after 3 days of culture. **(H)** T cells and antigen-presenting cells (APCs) were prepared from cGVHD or BMT recipients on day 60 as described in **(F)**, then APCs were pretreated with 10 U/mL IFNγ for 16 h. Data show the percentage of T~G~ or T~HSC~ that underwent one or more cell division after 3 days of culture. Data represent mean ± SEM \[*n* = 6 **(A,B)**, *n* = 4 **(E)**, *n* = 3 **(G,H)**\] from one of two independent experiments. \**P* ≤ 0.05; \*\**P* ≤ 0.01; \*\*\**P* ≤ 0.001 \[**(B,E,G)**; T~G~ vs. T~HSC~, **(H)**; and IFNγ (−) vs. IFNγ (+)\].](fimmu-08-01842-g004){#F4}

T~G~ Recognize Host Antigens through both Direct and Indirect Pathways {#S3-5}
----------------------------------------------------------------------

In the chronic phase of GVHD models, APCs are classified into host radioresistant non-hematopoietic cells or donor BM-derived hematopoietic cells. The former directly present complexes of host-type minor histocompatibility antigen (miHA)-derived peptide and MHC molecule to donor T cells, whereas the latter uptake host-type miHA from host radioresistant non-hematopoietic cells and present miHA-peptide/MHC complexes to donor-T cells through an indirect pathway. To investigate the allo-recognition pathway that contributes to the maintenance of T~G~ and T~HSC~ populations after allo-HSCT, we cocultured T~G~ or T~HSC~ with BMT recipient-derived APCs 49 days after allo-HSCT. To examine the direct pathway, we used radio-resistant host-derived non-hematopoietic cells that present endogenous host-type antigens (Figures [4](#F4){ref-type="fig"}F,G). To examine the indirect pathway, we used donor-derived T cell/NK cell-depleted hematopoietic cells containing professional APCs, which uptake and then present host antigens. We also used untreated C3H.SW mouse-derived hematopoietic cells and non-hematopoietic cells to examine the direct pathway that is involved in the early induction of effector T~G~. CFSE-dilution assays demonstrated that neither CD4^+^ nor CD8^+^ T~G~ proliferated in response to coculture with non-hematopoietic cells prepared from BMT recipient or untreated C3H.SW mice. In contrast, both CD4^+^ and CD8^+^ T~G~ proliferated when cocultured with hematopoietic cells from C3H.SW mice (direct pathway) and to a lesser extent when cocultured with hematopoietic cells from BMT recipients (indirect pathway) (Figure [4](#F4){ref-type="fig"}G). T~HSC~ displayed a similar proliferative response except that a small proportion of CD8^+^ T~HSC~ proliferated in response to coculture with non-hematopoietic cells. Considering that host-type hematopoietic APCs are completely absent in mice suffering cGVHD (data not shown), these results suggest that indirect host antigen presentation by donor-derived hematopoietic cells may be involved in the maintenance of T~G~ in cGVHD-affected organs.

Since inflammatory factors such as IFNγ modify antigen processing by inducing expression of immunoproteasomes and MHC molecules ([@B28]), we performed similar donor T cell and APC *ex vivo* coculture experiments with APCs that had been pretreated with 10 U/mL IFNγ for 16 h, which induced the expression of MHC class I and MHC class II on both hematopoietic and non-hematopoietic APCs. IFNγ pretreatment did not affect antigen presentation by non-hematopoietic APCs (Figure [4](#F4){ref-type="fig"}H). However, IFNγ pretreatment of hematopoietic APCs significantly increased the proliferation of CD4^+^ and CD8^+^ T~G~ in both direct and indirect pathway-dependent settings. In contrast, IFNγ pretreatment of hematopoietic APCs significantly suppressed the direct pathway-dependent proliferation of CD4^+^ T~HSC~ and indirect pathway-dependent proliferation of CD8^+^ T~HSC~. These results suggest that IFNγ expression in cGVHD-affected tissues may cause prolonged dominance of T~G~ among CD8^+^ T cells.

Selective Depletion of T~G~ or T~HSC~ Failed to Ameliorate the Pathology of cGVHD {#S3-6}
---------------------------------------------------------------------------------

To determine the involvement of T~G~ and T~HSC~ in the pathogenesis of cGVHD, we selectively depleted T~G~, T~HSC~, or both T~G~ and T~HSC~ from cGVHD mice using Thy1.1/1.2 congenic markers and an anti-Thy1.2 depleting mAb (Figure [5](#F5){ref-type="fig"}A). This protocol resulted in \>95% depletion of Thy1.2^+^ T cells from cGVHD-affected organs from day 35 to the end of our experiments (Figure [5](#F5){ref-type="fig"}B). Unexpectedly, survival rate, fibrotic changes, and inflammatory cell infiltration in cGVHD-affected organs were not ameliorated by the depletion of T~G~ (Figures [5](#F5){ref-type="fig"}C--E), despite the predominance of functionally competent T~G~ in the cGVHD-affected organs of untreated cGVHD mice. These results suggest that T~G~ alone are not responsible for the development and/or maintenance of the histopathology of cGVHD. On the other hand, survival was markedly reduced in the T~HSC~-depleted group, in which all mice died within approximately 3 weeks of initial antibody treatment (Figure [5](#F5){ref-type="fig"}F). This lethal exacerbation of GVHD was not due to the depletion of Thy1^+^ HSCs by the anti-Thy1.2^+^ antibody, because the number of CD48^−^ CD150^+^ lineage^−^ c-Kit^+^ Sca1^+^ long-term HSCs was equivalent between the cGVHD and T~HSC~-depleted groups (Figure [5](#F5){ref-type="fig"}G). In addition, there was no significant difference in the frequency of Foxp3^+^ liver-infiltrating CD4^+^ T cells between the cGVHD and T~HSC~-depleted groups, suggesting that the lethal exacerbation of GVHD in the T~HSC~-depleted group could not be attributed to the loss of Foxp3^+^ regulatory T cells (Figure [5](#F5){ref-type="fig"}H). Importantly, simultaneous depletion of T~G~ and T~HSC~ rescued cGVHD mice from the lethal exacerbation of disease induced by the depletion of T~HSC~ alone (Figure [5](#F5){ref-type="fig"}F). These results suggest that neither T~G~ nor T~HSC~ are solely responsible for cGVHD and that the lethal exacerbation of GVHD induced by T~HSC~ depletion is mediated by T~G~.

![Both T~G~ and T~HSC~ are involved in the pathogenesis of chronic graft-versus-host disease (cGVHD). **(A)** Schematic of the *in vivo* depletion study. T~G~ (T~G~-dep), T~HSC~ (T~HSC~-dep), or both T~G~ and T~HSC~ (T~G~/~HSC~-dep) were selectively depleted from cGVHD mice using the Thy1.1/1.2 congenic markers and an anti-Thy1.2 depleting mAb. Recipient mice received Thy1.1^+^ T-cell-depleted bone marrow (TCD BM) and Thy1.2^+^ splenic T cells, Thy1.2^+^ TCD BM and Thy1.1^+^ splenic T cells, or Thy1.2^+^ TCD BM and Thy1.2^+^ splenic T cells from B6 donors and were then treated with an mThy1.2 antibody or a control Ab on days 21 and 24 after transplantation, and weekly thereafter until day 63. **(B)** Depletion efficiency of anti-Thy1.2 mAb on Thy1.2^+^ T cells in the liver. **(C)** Survival data are combined from three independent experiments (*n* = 12--15). **(D)** Representative HE images and **(E)** histological scoring of the salivary glands, skin, liver, and lung from T~G~-dep and cGVHD (*n* = 5) mice on day 63. Scale bars, 50 µm. **(F)** Survival of cGVHD, T~HSC~-dep, and T~G~/~HSC~-dep group mice. Data are combined from three independent experiments (*n* = 12--15). **(G)** Number of HSCs (CD48^−^ CD150^+^ LSK) in the BM on day 28 after transplantation (7 days after T~HSC~ depletion). **(H)** Proportion of Foxp3^+^ cells within the liver CD4^+^ T~G~ population on day 28 after transplantation. Data in **(B,E,G,H)** represent mean ± SEM (*n* = 3 for the cGVHD group; *n* = 4 for the T~HSC~-dep group) from one of three independent experiments. n.s., not significant; \**P* ≤ 0.05; \*\**P* ≤ 0.01; and \*\*\**P* ≤ 0.001 (comparisons as indicated).](fimmu-08-01842-g005){#F5}

T~HSC~ Suppress Activation of T~G~ {#S3-7}
----------------------------------

The observation that simultaneous depletion of T~G~ and T~HSC~ ameliorated cGVHD while selective depletion of T~G~ or T~HSC~ failed to ameliorate cGVHD suggests that an interaction exists between these two distinct T cell populations. To investigate this interaction further, we examined the effects of T~HSC~ depletion on the number and function of T~G~. Since T~HSC~-depleted mice died within 3 weeks of depletion (day 21), analyses were performed on days 28 and 35. There were no significant differences in liver and lung T~G~ numbers between the T~HSC~-depleted and cGVHD groups (Figure [6](#F6){ref-type="fig"}A). In addition, the frequency of BrdU^+^ (proliferating) cells within the T~G~ population and the expression levels of CD44, CD25, and CD69 on T~G~ cells were equivalent between the T~HSC~-depleted and cGVHD groups (Figures [6](#F6){ref-type="fig"}B,C). However, the proportion of IFNγ^+^ and TNFα^+^ cells among liver-infiltrating CD4^+^ and CD8^+^ T~G~ cells was higher in the T~HSC~-depleted group compared to the cGVHD group on both days 28 and 35 (Figure [6](#F6){ref-type="fig"}D and data not shown). These results suggest that T~HSC~, despite being 10--100 times lesser in number than T~G~ at the time of depletion, inhibit inflammatory cytokine production by T~G~ and play a critical role in preventing lethal exacerbations of GVHD.

![T~HSC~ suppress activation of T~G~. T~HSC~ were selectively depleted from chronic graft-versus-host disease (cGVHD) mice as indicated in Figure [5](#F5){ref-type="fig"}A. **(A)** Numbers of CD4^+^ and CD8^+^ T~G~ from the liver and lung of T~HSC~-dep and cGVHD on day 28, 7 days after commencing T~HSC~ depletion by mThy1.2 antibody administration. **(B)** Proportion of BrdU^+^ cells within the CD4^+^ or CD8^+^ T cell populations in the liver and lung of T~HSC~-dep and cGVHD mice injected 1 h earlier with 1 mg of BrdU, 28 days after transplantation. Data in **(A,B)** represent mean ± SEM (*n* = 3 for the cGVHD group; *n* = 4 for the T~HSC~-dep group) from one of three independent experiments. **(C)** Representative flow cytometry plots showing the expression of activation markers on CD8^+^ T~G~ from the liver of T~HSC~-dep or cGVHD recipients. **(D)** Liver T cells were collected from cGVHD or T~HSC~-dep group mice and were restimulated with PMA and ionomycin *ex vivo*. Proportions of intracellular IFNγ- or TNFα-positive cells among CD4^+^ and CD8^+^ T~G~. Data represent mean ± SEM (*n* = 3 for the cGVHD group; *n* = 4 for the T~HSC~-dep group) from one of three independent experiments. n.s., not significant; \**P* ≤ 0.05.](fimmu-08-01842-g006){#F6}

T~G~ Suppress the Accumulation of T~HSC~ in cGVHD-Affected Organs {#S3-8}
-----------------------------------------------------------------

Finally, we examined the effects of T~G~ depletion on the number and function of T~HSC~. In kinetic studies of CD4^+^ and CD8^+^ T cell number in the liver, T~G~ rapidly decreased after anti-Thy1.2 mAb treatment in the T~G~-depleted group, whereas T~HSC~ increased to numbers approximately 10-fold higher than the cGVHD group between days 35 and 63 (Figure [7](#F7){ref-type="fig"}A). By day 63 after allo-HSCT, the number of T~HSC~ (particularly CD4^+^ T~HSC~) in the T~G~-depleted group had increased to levels comparable to the sum of T~G~ and T~HSC~ numbers in the cGVHD group (Figure [7](#F7){ref-type="fig"}B). To determine whether this increase in T~HSC~ number was due to an increase in T~HSC~ proliferation, we performed BrdU labeling on day 63 (Figure [7](#F7){ref-type="fig"}C). The proportion of BrdU^+^ cells among liver-infiltrating CD4^+^ and CD8^+^ T~HSC~ was significantly higher in the T~G~-depleted group, outnumbering the sum of BrdU^+^ T~G~ and T~HSC~ in the cGVHD group. There was no significant difference in the frequency of Foxp3^+^ cells among CD4^+^ T cells between the cGVHD and T~G~-depleted groups (Figure [7](#F7){ref-type="fig"}D). The majority of CD8^+^ T~HSC~ in the liver and lung, but not in the spleen, of T~G~-depleted group mice were CD44^hi^ effector T cells and had increased expression of the activation markers CD25 and CD69 (Figure [7](#F7){ref-type="fig"}E). The total proportion of IFNγ^+^ or TNFα^+^ cells among liver-infiltrating CD4^+^ and CD8^+^ T cells was equivalent between T~G~-depleted and cGVHD group mice (Figure [7](#F7){ref-type="fig"}F). However, the cellular composition of these populations switched from predominately T~G~ in the cGVHD group to predominately T~HSC~ in the T~G~-depleted group. Collectively, these results demonstrate that the proliferation and activation of T~HSC~ are augmented by T~G~ depletion in cGVHD-affected organs. This change appears to compensate in part for the decrease in T~G~ numbers and is likely to contribute to the histopathology observed in the cGVHD affected organs of the T~G~-depleted group.

![T~G~ suppress accumulation of T~HSC~. T~G~ were selectively depleted from chronic graft-versus-host disease (cGVHD) mice as indicated in Figure [5](#F5){ref-type="fig"}A. **(A)** Numbers of CD4^+^ and CD8^+^ T~G~ and T~HSC~ in the liver, lung, and spleen of T~G~-dep and cGVHD mice. **(B)** Numbers of CD4^+^ and CD8^+^ T~G~ and T~HSC~ in the liver, lung, and spleen 63 days after transplantation. n.s., not significant; \**P* ≤ 0.05 (T~HSC~ from cGVHD vs. T~HSC~ from T~G~-dep). **(C)** Proportion of BrdU^+^ cells within the CD4^+^ or CD8^+^ T cell populations in the liver, lung, and spleen of T~G~-dep and cGVHD mice injected 1 h earlier with 1 mg of BrdU, 63 days after transplantation. Data represent mean ± SEM (*n* = 6 for the cGVHD group; *n* = 3 for the T~G~-dep group) from one of three independent experiments. n.s., not significant; \**P* ≤ 0.05; \*\**P* ≤ 0.01; and \*\*\**P* ≤ 0.001 (T~HSC~ from cGVHD vs. T~HSC~ from T~G~-dep). **(D)** Proportion of Foxp3^+^ cells within the liver CD4^+^ T cell population on day 63 after transplantation. **(E)** Representative flow cytometry plots showing the expression of activation markers on CD8^+^ T~HSC~ from the liver and spleen of T~G~-dep or cGVHD recipients. **(F)** Liver T cells were collected from cGVHD or T~G~-dep group mice and were restimulated with PMA and ionomycin *ex vivo*. Proportions of CD4^+^ and CD8^+^ T~G~ and T~HSC~ positive for intracellular IFNγ and TNFα were analyzed by flow cytometry. Data represent mean ± SEM (*n* = 6 for the cGVHD group; *n* = 3 for the T~G~-dep group) from one of three independent experiments.](fimmu-08-01842-g007){#F7}

Discussion {#S4}
==========

Until now, the contribution of T~G~ to the development and maintenance of cGVHD has remained unclear. In this study, we established a model of cGVHD that recapitulates the pathology of clinical cGVHD. We demonstrated that functional T~G~ persist and predominate over T~HSC~ in the organs affected by cGVHD. Furthermore, our depletion studies revealed the existence of an unexpected bidirectional regulatory interaction between T~G~ and T~HSC~: T~G~ suppress the proliferation and accumulation of T~HSC~ in cGVHD-affected organs, whereas T~HSC~ suppress the activation of T~G~ in affected organs, thereby preventing exacerbations of GVHD mediated by T~G~.

There are few mouse models of cGVHD that accurately recapitulate the histopathology and disease course of clinical cGVHD. Recently, a B6 (H2^b^) Recent (H2^k^) allo-HSCT model, which utilized cyclophosphamide and total body irradiation as a conditioning regimen, was demonstrated to induce fibrotic changes in the lungs, liver, and SG ([@B29], [@B30]). The developmental course of this model recapitulated cGVHD that develops without preceding aGVHD. Mice in our B6→C3H.SW minor mismatched allo-HSCT model also developed several histological aspects of clinical cGVHD, such as fibrotic changes in the skin, liver, lungs, and SG following aGVHD, which may recapitulate the acute to chronic transition in clinical GVHD.

In our cGVHD model, a large number of T~G~ persisted in cGVHD-affected organs up to day 63 after allo-HSCT. On the other hand, peripheral reconstitution of T~HSC~ became obvious from about 4--5 weeks after allo-HSCT and gradually increased thereafter. As a result, both T~G~ and T~HSC~ infiltrated the affected organs in late phase cGVHD with an unexpected predominance of T~G~. In an aGVHD model, Zhang et al. ([@B31]) have described a CD44^lo^ CD62L^hi^ IL-7Rα^hi^ CD8^+^ memory stem cell population that maintain CD8^+^ T~G~ in the recipient for a long period of time. In contrast, in our cGVHD model, the majority of T~G~ in affected organs had a CD44^hi^ CD62L^lo^ IL-7Rα^lo^ effector phenotype. Despite the higher proportion of PD-1^+^ or KLRG-1^+^ phenotypically exhausted or senescent populations within the CD8^+^ T~G~ population, the potential for inflammatory cytokine production and *in situ* proliferation was almost equivalent between T~G~ and T~HSC~. Masopust et al. ([@B32]) have reported that KLRG-1^+^ PD-1^−^ senescent CD8^+^ T cells induced by a heterologous prime-boost vaccination show strong cytotoxic activity. Thus, KLRG-1^+^ PD-1^−^ CD8^+^ T~G~ may be involved in the cellular immunopathogenesis of cGVHD.

In the cGVHD affected liver and lung, a significant proportion of CD8^+^ T~G~ were actively proliferating even at day 63, suggesting that T~G~ maintenance is a dynamic process controlled by cell proliferation and cell death. Considering that T~G~ do not proliferate in response to direct presentation of host antigens by non-hematopoietic cells, it appears that donor HSC-derived APCs capture host alloantigens and indirectly present them to T~G~ in cGVHD-affected organs. An intriguing question that remains is whether T~G~ clones that expanded in response to direct presentation in the acute phase cross-react to indirect presentation in the chronic phase, or whether indirect presentation-reactive T~G~ clones are independently expanded by donor-derived APCs after repopulation of these cells in the peripheral tissues. A better understanding of the clonal response of T~G~ after allo-HSCT and the pathological significance of this process may facilitate the early diagnosis and treatment of cGVHD.

The finding that depletion of the small T~HSC~ population potentiated the inflammatory cytokine production of T~G~ and caused a T~G~-mediated acute exacerbation of GVHD suggests that reconstitution of T~HSC~ is important for limiting excessive activation of T~G~ and promoting acute to chronic disease transition following allo-HSCT. Impaired inhibition of T~G~ by T~HSC~ may account for the GVHD that is refractory to immunosuppressive therapy with a calcineurin inhibitor, which inhibits both T~G~ activation and T~HSC~ development ([@B33]). However, the molecular and cellular mechanisms underlying the inhibition of T~G~ activation by T~HSC~ remain to be elucidated.

Reconstitution of T~HSC~ is markedly delayed and suppressed in the presence of GVHD ([@B16]). In the early phase of aGVHD, CD4^+^ T~G~ impair the production of common lymphoid progenitors through the destruction of the hematopoietic niche in the BM, resulting in a severe reduction in T- and B-lymphocyte genesis ([@B17], [@B34]). T~G~ also impair thymopoiesis by disrupting the thymic epithelium ([@B35]). Thus, T~G~ may suppress T~HSC~ reconstitution by impairing primary lymphoid tissues. In the present study, depletion of T~G~ resulted in a rapid increase in the number of T~HSC~ in the liver and lung. Interestingly, increased numbers of T~HSC~ in the T~G~-depleted group partially compensated for the decreased numbers of T~G~ in cGVHD-affected organs. This finding points to the possible existence of a niche that provides antigenic signals and survival factors to pathogenic T cells of T~G~ or T~HSC~ origin. Such a "pathogenic T cell niche" might have a fixed pool capacity, meaning that T~G~ and T~HSC~ compete with each other for space in the niche during cGVHD.

In summary, we have characterized the cellular mechanisms underlying the maintenance of pathogenic T cells in a clinically relevant cGVHD model. Both T~G~ and T~HSC~ with the potential to proliferate and produce inflammatory cytokines infiltrated cGVHD-affected organs, with the number and/or activity of T~G~ and T~HSC~ being reciprocally regulated by each other. In addition, our depletion studies highlight the importance of reciprocal tuning of the balance between T~G~ and T~HSC~, which requires the successful reconstitution of T~HSC~, in the control of GVHD. By elucidating the interactions between T~G~ and T~HSC~, our findings will help guide the development of novel therapeutic strategies for the prevention and treatment of cGVHD.
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